



ERRATUM

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

Christoph Wanner, Mark E. Cooper, Odd Erik Johansen, Robert Toto, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, Egon Pfarr, Sven Schnaidt, Maximilian von Eynatten, Jyothis T. George, Nicholas D. Gollop, Nikolaus Marx, John H. Alexander, Bernard Zinman and Vlado Perkovic, on behalf of the CARMELINA investigators

Clinical Kidney Journal, sfaa225, <https://doi.org/10.1093/ckj/sfaa225>

In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: 'Point estimates on the left side of the curve indicate a positive effect for LINA.'